Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 10/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22923019 | 0.80 | LPL (0.46) | IDO1TDO2LPLLIPGIRAK4 | |
| SCHEMBL31153 | 0.73 | GPR3 (0.48) | LPLLIPGIRAK4PRMT5WDR77 | |
| SCHEMBL16291887 | 0.73 | NQO2 (0.49) | IDO1TDO2LPLLIPGIRAK4 | |
| SCHEMBL30895247 | 0.71 | IDO1 (0.38) | IDO1TDO2LPLLIPGIRAK4 | |
| SCHEMBL29856116 | 0.71 | LPL (0.39) | IDO1TDO2LPLLIPGIRAK4 | |
| SCHEMBL20186942 | 0.71 | LPL (0.39) | IDO1TDO2LPLLIPGIRAK4 | |
| SCHEMBL15947140 | 0.70 | LPL (0.44) | LPLLIPGIRAK4F11PRMT5 | |
| SCHEMBL26923911 | 0.70 | LPL (0.47) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL30692214 | 0.70 | LPL (0.47) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL10171026 | 0.70 | CSF1R (0.43) | IDO1TDO2LPLLIPGIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3444246-B1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | SHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-10464927-B2 | 2,4-disubstituted pyrimidines as CDK inhibitors | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2019-11-05 | — | — | US | disclosed |
| US-20190071427-A1 | 2,4-Disubstituted Pyrimidine Derivative as CDK Inhibitor and Use Thereof | CHENGDU JINRUI FOUNDATION BIOTECH CO., LTD. (CN) | 2019-03-07 | — | — | US | disclosed |
| EP-3444246-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | Shanghai Xunhe Pharmaceutical Technology Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071427-A1 | 2,4-Disubstituted Pyrimidine Derivative as CDK Inhibitor and Use Thereof | CDK4, CDK2, CDK6 | IDO1 2955/4885TDO2 2195/4885LPL 3689/4885 |
| US-10464927-B2 | 2,4-disubstituted pyrimidines as CDK inhibitors | CDK4, CDK2, CDK6 | IDO1 3078/4885TDO2 2385/4885LPL 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.